Trial Profile

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ridaforolimus (Primary)
Indications Coronary artery restenosis
Focus Adverse reactions; Therapeutic Use
Acronyms IonMAN II
Sponsors Medinol

Most Recent Events

21 Nov 2024 Planned End Date changed from 1 Aug 2029 to 1 Oct 2031.
21 Nov 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.
21 Nov 2024 Planned initiation date changed from 1 Oct 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com